epidiolex
Generic: cannabidiol
epidiolex: developed by 2 companies · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (2)
| Company | Phase |
|---|---|
| GW PHARMACEUTICALS PLC (GWPH) | Phase 3 |
| Jazz Pharmaceuticals plc (JAZZ) | Approved |
Clinical Trials (1)
Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox- Gastaut Syndrome (LGS), Dravet Syndrome (DS) and Tuberous Sclerosis Complex (TSC)
Frequently asked questions
Who is developing epidiolex?
epidiolex is being developed by GW PHARMACEUTICALS PLC, Jazz Pharmaceuticals plc.
How many clinical trials involve epidiolex?
BioSniper tracks 1 clinical trial involving epidiolex.
Get deeper analysis on epidiolex
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis